Video

Dr. Cohn on Frontline Therapies in Metastatic Pancreatic Cancer

Allen L. Cohn, MD, medical oncologist, Rocky Mountain Cancer Centers, discusses frontline therapies in metastatic pancreatic cancer.

Allen L. Cohn, MD, medical oncologist, Rocky Mountain Cancer Centers, discusses frontline therapies in metastatic pancreatic cancer.

For many years, the frontline standard of care in metastatic pancreatic cancer was gemcitabine monotherapy. Subsequently, FOLFIRINOX was introduced into the paradigm. Although the regimen can induce high response rates, it has a high incidence of toxicity. Then, the combination of gemcitabine and nab-paclitaxel (Abraxane) was found to show similar efficacy to that of FOLFIRINOX in the frontline setting. Although the combination has shown a lower response rate than what has been seen with FOLFIRINOX, it has a lower rate of toxicity, explains Cohn.

In terms of adjuvant chemotherapy, gemcitabine was the mainstay for many years. However, as in the frontline setting, FOLFIRINOX was found to be superior to gemcitabine monotherapy in terms of overall survival and progression-free survival, concludes Cohn.

Related Videos
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Sundar Jagannath, MBBS
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Paolo Tarantino, MD
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Shella Saint Fleur-Lominy, MD, PhD
Benjamin Levy, MD
Nader Sanai, MD, chief, Neurosurgical Oncology, director, Ivy Brain Tumor Center, Barrow Neurological Institute